^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
Sysmex Corp

i
Other names: Oxford Gene Technology | Oxford Gene Technology IP Ltd. | Sysmex Corporation | Cytocell Limited | Cytocell Ltd | Sysmex Inostics | sysmex | inostics | Sysmex Inostics GmbH | Sysmex Inostics, Inc.
Related tests:
Evidence

News

2ms
OGT expands NGS operations to state-of-the-art facility in Oxford Technology Park (Sysmex Press Release)
"OGT...announces the opening of state-of-the-art facilities within the Oxford Technology Park. The move represents a multi-million-pound investment, fuelled by consistent company growth and growing customer demand. Equipped with cutting-edge technology, the facilities will drive development of OGT’s trusted SureSeq™ next generation sequencing (NGS) product portfolio, as well as deliver expert-led training and enhanced opportunities for collaboration."
Clinical
|
SureSeq™ CLL + CNV Panel • SureSeq™ Germline Breast Cancer + CNV Panel • SureSeq™ Myeloid MRD Panel • SureSeq™ Myeloid Plus Panel • SureSeq™ Pan-Myeloid Panel
5ms
OGT to premiere SureSeq Myeloid MRD panel for AML disease monitoring at AMP (Sysmex Press Release)
"OGT, A Sysmex Group Company, will showcase its soon to be launched SureSeq™ Myeloid MRD Panel at booth #1423 at the Association for Molecular Pathology (AMP) 2023 Annual Meeting & Expo, 14-18th November in Salt Lake City. The Next-generation sequencing (NGS) panel represents a substantial improvement on conventional flow cytometry and qPCR methods of detecting measurable residual disease (MRD) in acute myeloid leukaemia (AML) samples—providing outstanding sensitivity and coverage uniformity in one rapid and cost-effective assay."
Clinical
|
SureSeq™ Myeloid MRD Panel
6ms
OGT and Intelliseq launch NGS reporting and interpretation for all myeloid malignancy panels (Sysmex Press Release)
"OGT, A Sysmex Group Company...and Intelliseq...are delighted to announce the release of GeneSpect™ Somatic Reporter for use with OGT’s SureSeq™ portfolio of next generation sequencing (NGS) panels. This advanced analytical reporting solution pairs state-of-the-art variant interpretation and reporting with OGT’s class-leading NGS panels and bioinformatics solutions. Users of SureSeq Myeloid panels can now benefit from insightful tertiary reporting for all myeloid malignancy content and variants with the GeneSpect Somatic Reporter."
Launch
|
SureSeq™ CLL + CNV Panel • SureSeq™ Germline Breast Cancer + CNV Panel • SureSeq™ Myeloid Plus Panel • SureSeq™ Pan-Myeloid Panel
6ms
OGT and Intelliseq forge partnership to advance clinical and biological insight from NGS data (Sysmex Press Release)
"OGT, a Sysmex Group Company...is delighted to announce its new partnership with Intelliseq...This collaboration combines OGT's expansive SureSeq™ NGS portfolio with Intelliseq's state-of-the-art iFlow™ engine, resulting in a thorough and comprehensive NGS workflow—from sample to report. This advancement will greatly enhance lab productivity by automating the interpretation of NGS data and deliver actionable insights into cancer."
Licensing / partnership
8ms
Sysmex : OncoGuide NCC Oncopanel System Receives Insurance Coverage as a Companion Diagnostic for Futibatinib, a Treatment for Advanced Biliary Tract Cancer (Market Screener)
"Sysmex Corporation...is now covered by health insurance in Japan as a companion diagnostic for futibatinib,1 a treatment for unresectable biliary tract cancer2 harboring FGFR2 gene fusions3 that has progressed after chemotherapy. Futibatinib was developed by Taiho Pharmaceutical Co., Ltd....Riken Genesis Co., Ltd (HQ: Shinagawa-ku, Tokyo, Japan; President: Kenji Iwakabe), a subsidiary of Sysmex, will begin assay services in Japan corresponding to this insurance coverage from September 2023."
Reimbursement
|
OncoGuide™ NCC Oncopanel System
|
Lytgobi (futibatinib)
10ms
OGT announces commercial partnership with Applied Spectral Imaging (Sysmex Press Release)
"OGT, a Sysmex Group Company...announces a new commercial partnership with Applied Spectral Imaging (ASI)...The agreement will grant OGT rights to market ASI’s proprietary cytogenetic imaging and analysis solutions in Great Britain, establishing a strategic partnership that combines the strengths of OGT’s CytoCell® FISH portfolio with ASI’s imaging and analysis capabilities to deliver operational efficiency in end user’s laboratories."
Licensing / partnership
12ms
Sysmex Inostics exhibits at American Association for Cancer Research Annual Meeting 2023 in Orlando (Sysmex Press Release)
"Sysmex Inostics Inc...is exhibiting at the American Association for Cancer Research® (AACR) Annual Meeting 2023 in Orlando, FL from April 16, 2023, through April 19, 2023. The company is exhibiting at 'Booth 1325' to meet with the over 20,000 global cancer research professionals in attendance."
Clinical data
1year
Sysmex Inostics and Genomic Testing Cooperative form partnership to accelerate therapeutic discovery and development (Genomic Testing Cooperative Press Release)
"Sysmex Inostics Inc...and Genomic Testing Cooperative (GTC), based in Irvine, California, formed a strategic partnership for Sysmex Inostics to commercialize GTC’s tissue and liquid biopsy solid tumors and hematology assay services to biopharma customers. This includes GTC’s Solid Tumor Profile Plus, Liquid Trace Solid Tumor Profile, Liquid Trace Hematology Profile, and Hematology Profile Plus assay services."
Licensing / partnership
|
Hematology Profile Plus • Liquid Trace™ Hematology • Liquid Trace™ Solid Tumor • Solid Tumor Profile Plus
1year
Sysmex, Cerca Biotech sign distribution agreement on breast cancer assay (Genomeweb)
"Sysmex Europe and Cerca Biotech said...that they have inked a deal for Sysmex to distribute Cerca's molecular breast cancer assay in 13 European markets...German diagnostic firm Cerca's RT-qPCR MammaTyper assay is used to identify breast cancer subtypes through quantitative measurement of mRNA expression status for four genes in breast cancer tissue."
Licensing / partnership
|
MammaTyper® Kit
1year
OGT first to achieve IVDR-certification for FISH probes (Sysmex Press Release)
"OGT, A Sysmex Group Company, announces that IVDR-certification has been granted for eight CytoCell® fluorescence in situ hybridisation (FISH) probes, important for patient management in haematological cancers and prenatal conditions. This award places OGT as the first manufacturer of FISH probes to obtain the new IVDR certification on its products—demonstrating continued safety, reliability and effectiveness under this substantially more stringent regulation."
European regulatory
over1year
Sysmex applies for a partial change for the OncoGuide™ NCC Oncopanel System as a companion diagnostic for the treatment of advanced biliary tract cancer (Sysmex Press Release)
"Sysmex Corporation...applied on September 2, 2022 for a partial change of the manufacturing and marketing approval for the OncoGuide™ NCC Oncopanel System, a gene mutation analysis set (the 'System') to include its use as a companion diagnostic for patients with advanced biliary tract cancer harboring FGFR2 gene rearrangements, including gene fusions."
Clinical
|
OncoGuide™ NCC Oncopanel System
almost2years
Sysmex forms strategic alliance with QIAGEN to provide global cancer companion diagnostics that uses ultra-sensitive liquid biopsy NGS technology (Sysmex Press Release)
"Sysmex Corporation...has announced today that it has formed a global strategic alliance with QIAGEN N.V...for the development of cancer companion diagnostics...Sysmex is working to strengthen its global relationship with pharmaceutical companies in order to develop companion diagnostics and timely launch them by capitalizing on Plasma-Safe-SeqS technology, a liquid biopsy developed by Sysmex using a next-generation sequencer (NGS), while leveraging QIAGEN’s experience in developing companion diagnostics."
Licensing / partnership
almost2years
Sysmex Inostics & QIAGEN highlight cancer companion diagnostics alliance at ASCO 2022 (PRNewswire)
"QIAGEN...and Sysmex Inostics combined forces in July 2021 to accelerate global companion diagnostic access. QIAGEN provides unparalleled global custom cancer companion diagnostics (CDx) development and commercialization capabilities utilizing Sysmex Inostics ultra-sensitive NGS liquid biopsy technology...will present the poster "Plasma RAS dynamics and anti-EGFR rechallenge efficacy in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials." Circulating tumor DNA (ctDNA) was analyzed and monitored using the Sysmex Inostics OncoBEAM™ RAS CRC Kit."
Clinical
|
OncoBEAM RAS CRC kit
almost2years
Sysmex Inostics expands blood test offerings for detection of acute myeloid leukemia (Sysmex Press Release)
"Sysmex Inostics...has expanded its offering of CLIA-validated tests to include AML-SEQ™, a focused panel to detect mutations of the three most prevalent genes found in Acute Myeloid Leukemia (AML) – IDH1/2 & NPM1...AML-MRD-SEQ is a more extensive panel for the detection of measurable residual disease (MRD) in 68 regions across 20 genes including the clinically established IDH1/2 and NPM1."
Clinical
|
SafeSEQ AML MRD Assay
2years
Sysmex Inostics introduces CLIA-validated highly sensitive HNSCC-SEQ testing services for head and neck cancer at the 2022 Molecular Medicine Tri-Conference (Sysmex Press Release)
"Sysmex Inostics...will introduce HNSCC-SEQ, a highly sensitive Plasma-Safe-SeqS and Next Generation Sequencing (NGS) assay service for head and neck squamous cell carcinomas (HNSCC), at the annual 2022 Molecular Medicine Tri-Conference being held Monday, February 21st through Wednesday, February 23rd in San Diego, California. The assay has a turn-around-time of 7-10 days and is available to researchers and clinicians."
Launch
|
SafeSEQ HNSCC assay
2years
University of Chicago clinical trial utilizes Sysmex Inostics highly effective HPV-SEQ test to measure HPV-DNA from blood of neck and throat cancer patients (Sysmex Press Release)
"Sysmex Inostics...announces the use of their HPV-SEQ test in the prospective University of Chicago clinical trial, 'Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer...HPV-SEQ, Sysmex Inostics ultra-sensitive quantitative, CLIA-validated, blood test for the detection of cell-free HPV 16/18 DNA (cfHPV-DNA), will be used in the trial to monitor personalized treatment and de-escalation of HPV positive oropharyngeal cancer (OPC) patients."
Clinical
|
SafeSEQ HPV Test